Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity

Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8α+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8α+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3–/– mice were defective in cross-presentation, and Batf3–/– mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3–/– mice. These results suggest an important role for CD8α+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.

[1]  J. Villadangos,et al.  The cell biology of cross‐presentation and the role of dendritic cell subsets , 2008, Immunology and cell biology.

[2]  K. Hogquist,et al.  Identification of a novel population of Langerin+ dendritic cells , 2007, The Journal of experimental medicine.

[3]  G. Belz,et al.  Skin-Derived Dendritic Cells Can Mediate Deletional Tolerance of Class I-Restricted Self-Reactive T Cells1 , 2007, The Journal of Immunology.

[4]  E. Kremmer,et al.  CD103− and CD103+ Bronchial Lymph Node Dendritic Cells Are Specialized in Presenting and Cross-Presenting Innocuous Antigen to CD4+ and CD8+ T Cells1 , 2007, The Journal of Immunology.

[5]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[6]  M. Diamond,et al.  CD4+ T-Cell Responses Are Required for Clearance of West Nile Virus from the Central Nervous System , 2006, Journal of Virology.

[7]  M. Zenke,et al.  Towards an understanding of the transcription factor network of dendritic cell development. , 2006, Trends in immunology.

[8]  S. Ju,et al.  A Major Lung CD103 (αE)-β7 Integrin-Positive Epithelial Dendritic Cell Population Expressing Langerin and Tight Junction Proteins1 , 2006, The Journal of Immunology.

[9]  G. Belz,et al.  Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity , 2006, Nature Immunology.

[10]  R. Zinkernagel,et al.  Histological analysis of CD11c‐DTR/GFP mice after in vivo depletion of dendritic cells , 2005, Clinical and experimental immunology.

[11]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[12]  M. Bevan,et al.  CD8α+ Dendritic Cells Selectively Present MHC Class I-Restricted Noncytolytic Viral and Intracellular Bacterial Antigens In Vivo1 , 2005, The Journal of Immunology.

[13]  Li Wu,et al.  Cutting Edge: Generation of Splenic CD8+ and CD8− Dendritic Cell Equivalents in Fms-Like Tyrosine Kinase 3 Ligand Bone Marrow Cultures1 , 2005, The Journal of Immunology.

[14]  R. Flavell,et al.  Toll-like receptor 3 promotes cross-priming to virus-infected cells , 2005, Nature.

[15]  G. Belz,et al.  Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Karupiah,et al.  Cutting Edge: Conventional CD8α+ Dendritic Cells Are Generally Involved in Priming CTL Immunity to Viruses 1 , 2004, The Journal of Immunology.

[17]  G. Belz,et al.  Epidermal Viral Immunity Induced by CD8α+ Dendritic Cells But Not by Langerhans Cells , 2003, Science.

[18]  Damien Chaussabel,et al.  Relationships Among Murine CD11chigh Dendritic Cell Subsets as Revealed by Baseline Gene Expression Patterns1 , 2003, The Journal of Immunology.

[19]  Anantha Marri,et al.  B Cells and Antibody Play Critical Roles in the Immediate Defense of Disseminated Infection by West Nile Encephalitis Virus , 2003, Journal of Virology.

[20]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[21]  T. Schumacher,et al.  Redundancy of Direct Priming and Cross-Priming in Tumor-Specific CD8+ T Cell Responses1 , 2001, The Journal of Immunology.

[22]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[23]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[24]  M. Bevan,et al.  Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.

[25]  W. Wachsman,et al.  Repression of IL-2 Promoter Activity by the Novel Basic Leucine Zipper p21SNFT Protein1 2 , 2000, The Journal of Immunology.

[26]  W. Heath,et al.  Defective TCR expression in transgenic mice constructed using cDNA‐based α‐ and β‐chain genes under the control of heterologous regulatory elements , 1998, Immunology and cell biology.

[27]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[28]  M. Bevan.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay , 1976, The Journal of experimental medicine.

[29]  Shalin H. Naik,et al.  Steady-state and inflammatory dendritic-cell development , 2007, Nature Reviews Immunology.